Evidence map›Paper›PMID 34465981›Full record

ArticleDrug design, development and therapy2021

Puerarin Alleviates UUO-Induced Inflammation and Fibrosis by Regulating the NF-κB P65/STAT3 and TGFβ1/Smads Signaling Pathways.

Jingyu Wang, Shuke Ge, Yaqing Wang, Yi Liu, Lihua Qiu, Junying Li, Xin Huang, Li Sun

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Therapeutic potential ofFrontiers in pharmacology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jingyu WangDepartment of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.ORCID 0000-0003-1453-9587
Shuke GeDepartment of Emergency management, Liaoning Center for Disease Control and Prevention, Shenyang, 110000, Liaoning Province, People's Republic of China.ORCID 0000-0003-1972-2954
Yaqing WangDepartment of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.
Yi LiuDepartment of Anesthesiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan Province, People's Republic of China.
Lihua QiuDepartment of epigenetics, China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.
Junying LiDepartment of epigenetics, China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.
Xin HuangDepartment of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.
Li SunDepartment of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, People's Republic of China.
First Hospital of China Medical University · CNChina Medical University · CNAffiliated Hospital of North Sichuan Medical College · CNShenyang Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePuerarin (PR), a Chinese medicine rich in natural components, has been reported to display anti-fibrotic, antioxidant, anti-inflammatory and immunomodulatory properties. However, the protective mechanism of PR against unilateral ureteral obstruction (UUO)-mediated renal injury is not fully clarified. Therefore, the aim of this study was to investigate the effects of PR on UUO mice and its possible mechanisms.

methodsA total of 32 C57BL/6 mice were divided randomly into four groups (n=8): i) sham-operated group (Sham); ii) UUO group (UUO); iii) UUO + PR 50 mg/kg/day (UUO + PRL); and iv) UUO + PR 100 mg/kg/day (UUO + PRH). Continuous gavage administration for 14 days starting one week postoperatively, while the mice in Sham and UUO groups were given equal amounts of vehicle by the same means. All mice were then sacrificed and serum, 24-hour urine and tissue specimens were collected for renal function, histopathology, Western blot, immunohistochemistry.

resultsRenal function and histopathology revealed that PR improved UUO-mediated renal dysfunction and partially reversed tubular injury and tubulointerstitial fibrosis. Additionally, according to the results of Western blot and immunohistochemistry, PR inhibited the expression of inflammatory factors including IL-1β, IL-6, MCP-1 and ECM-related proteins including α-SMA, COL I and VIM. More importantly, the expression of fibrotic pathways TGF-β1, Smad3, p-Smad3 and inflammatory pathways NF-κB p65, NF-κB p-p65, STAT3, p-STAT3 were inhibited to various extents under the PR treatment, while Smad7 was upregulated.

conclusionThese findings indicate that PR may inhibit the recruitment of inflammatory factors and extracellular matrix (ECM) deposition through the regulation of the NF-κB p65/STAT3 and TGFβ1/Smads pathways, which alleviates the UUO-induced inflammatory and fibrotic response, thereby reversing renal injury.

Indexed as

AnimalsDisease Models, AnimalFibrosisInflammationIsoflavonesKidney DiseasesMaleMiceMice, Inbred C57BLSignal TransductionSmad ProteinsSTAT3 Transcription FactorTranscription Factor RelATransforming Growth Factor beta1Ureteral ObstructionIsoflavonespuerarinSmad ProteinsStat3 protein, mouseSTAT3 Transcription FactorTgfb1 protein, mouseTranscription Factor RelATransforming Growth Factor beta1CKDfibrosisinflammationpuerarinUUO

Identifiers

PMID34465981
PMCPMC8402986
OpenAlexW3193628022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.